Other inhibitors targeting bone resorption or RANKL-RANK signaling have also been reported to be effective in treating tumor progression and bone metastasis, including OPG-Fc (172), RANK-Fc (172), calcitonin (174), etc. Based on the observation of bisphosphonates and denosumab in treating bone metastasis, it will be reasonable to speculate that all of the other inhibitors modulation of hypercalcemia in cancer patients would likely lead to hypocalcemia. This evidence concerns the gene TNFRSF11A and Hypocalcemia.